Viatris vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 76)
Viatris logo

Viatris

LeaderHealthcare Tech

Generic Pharmaceuticals

Viatris (VTRS) reported ~$15.4B revenue in FY2024. Global generic and specialty pharmaceutical company formed by Pfizer's Upjohn spinoff merging with Mylan. HQ: Canonsburg, PA.

AI VisibilityBeta
Overall Score
B76
Category Rank
#73 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
75
Perplexity
71
Gemini
73

About

Viatris Inc. is a global pharmaceutical company formed in 2020 through the combination of Pfizer's off-patent branded drug unit (Upjohn) and Mylan, one of the world's largest generic drug manufacturers. The company manufactures, licenses, and distributes approximately 1,400 approved molecules across branded generics, complex generics, and a portfolio of iconic off-patent brands including Lipitor (atorvastatin), Viagra (sildenafil), EpiPen, and Xanax (alprazolam) sold in markets where these brands retain meaningful recognition and premium pricing.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

76
Overall Score
81
#73
Category Rank
#17
79
AI Consensus
71
stable
Trend
stable
75
ChatGPT
80
71
Perplexity
75
73
Gemini
77
80
Claude
86
73
Grok
85

Key Details

Category
Generic Pharmaceuticals
General
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Viatris
Generic Pharmaceuticals

Integrations

Viatris is classified as company (part of Pfizer). Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.